Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
So this year in San Antonio, we present the first data of a thermal cycle in combination with letrozole for patients that were treatment naive in a metastatic setting and had a hormone receptor positive. Her two negative breast cancer, a thermal cycle is a highly selective CD K four inhibitor with significant sparing of CD K six. This way compared to the already approved CD K 46 inhibitor, the molecule is able to block CD K four sparing CD K six and unnecessary toxicity. In order to reach better plasma concentration and inhibition of cancer cells, we treated 34 treatment naive patient with a thermy plus letrozole patient had a median age of 59 years. And uh in this cohort that they never received treatment for the uh metastatic setting. The safety of the drug was uh really good with the very favorable signals and promising anti tumor activity at 300 mg twice a day of the. There were few incidents of treatment related grade three neutropenia or higher and other A E were very low. There was no grade four or five A E observed in these study and from the preliminary activity of a thelast letrozole. Uh There was an objective response rate of 61% with the clinical benefit ratio at 24 weeks of 94%.
